West Nile virus: The complex biology of an emerging pathogen

Intervirology

Volumn 54, Issue 4, 2011, Pages 171-184

  Ulbert, Sebastian ^a  

^a FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

Author keywords

Emerging pathogen; Flavivirus; Immunity; Vaccination; West Nile virus; Zoonosis

Indexed keywords

VIRUS PROTEIN; WEST NILE VACCINE;

DRUG MECHANISM; EPIDEMIC; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS ENCEPHALITIS; VIRUS GENOME; VIRUS MENINGITIS; VIRUS PARTICLE; VIRUS STRAIN; VIRUS VIRULENCE; WEST NILE FEVER; WEST NILE FLAVIVIRUS; ZOONOSIS;

ANIMALS; BIRDS; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; EUROPE; GENOTYPE; HORSES; HUMANS; IMMUNE EVASION; INCIDENCE; NORTH AMERICA; VIRULENCE; WEST NILE FEVER; WEST NILE VIRUS;

AVES; EQUIDAE; FLAVIVIRUS; MAMMALIA; WEST NILE VIRUS;

EID: 79959285830     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000328320     Document Type: Review

References (104)

1. Smithburn KC, Hughes TP, Burke AW, Paul JH: A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg 1940;20:471-472.
2. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL: Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 2005;11:1174-1179. (Pubitemid 41045322)
3. Murray KO, Mertens E, Desprès P: West Nile virus and its emergence in the United States of America. Vet Res 2010;41:67.
4. Ward MP, Scheurmann JA: The relationship between equine and human West Nile virus disease occurrence. Vet Microbiol 2008;129:378-383.
5. Komar N, Langevin S, Hinten S, Nemeth N, Edwards E, Hettler D, Davis B, Bowen R, Bunning M: Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg Infect Dis 2003;9:311-322.
6. Gubler DJ, Kuno G, Markoff L: Flaviviruses; in Knipe DM, Howley PM (ed): Fields Virology, ed 5. Philadelphia, Lippincott Williams & Wilkins, 2007, pp 1155-1252.
7. Miller BR, Nasci RS, Godsey MS, Savage HM, Lutwama JJ, Lanciotti RS, Peters CJ: First field evidence for natural vertical transmission of West Nile virus in Culex univittatus complex mosquitoes from Rift Valley Province, Kenya. Am J Trop Med Hyg 2000;62:240-246. (Pubitemid 30257584)
8. Nasci RS, Savage HM, White DJ, Miller JR, Cropp BC, Godsey MS, Kerst AJ, Bennett P, Gottfried K, Lanciotti RS: West Nile virus in overwintering Culex mosquitoes, New York City, 2000. Emerg Infect Dis 2001;7:742-744.
9. Hubálek Z, Halouzka J: West Nile fever - a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis 1999;5:643-650. (Pubitemid 29493766)
10. May FJ, Davis CT, Tesh RB, Barrett AD: Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas. J Virol 2011;85:2964-2974.
11. Bin H, Grossman Z, Pokamunski S, Malkinson M, Weiss L, Duvdevani P, Banet C, Weisman Y, Annis E, et al: West Nile fever in Israel 1999-2000: from geese to humans. Ann N Y Acad Sci 2001;951:127-142.
12. LaDeau SL, Kilpatrick AM, Marra PP: West Nile virus emergence and large-scale declines of North American bird populations. Nature 2007;447:710-713. (Pubitemid 46889724)
13. Barzon L, Franchin E, Squarzon L, Lavezzo E, Toppo S, Martello T, Bressan S, Pagni S, Cattai M, Piazza A, Pacenti M, Cusinato R, Palù G: Genome sequence analysis of the first human West Nile virus isolated in Italy in 2009. Euro Surveill 2009;14.
14. Papa A, Xanthopoulou K, Gewehr S, Mourelatos S: Detection of West Nile virus lineage 2 in mosquitoes during a human outbreak in Greece. Clin Microbiol Infect doi: 10.1111/j.1469-0691.2010.03438.x
15. Sirbu A, Ceianu CS, Panculescu-Gatej RI, Vazquez A, Tenorio A, Rebreanu R, Niedrig M, Nicolescu G, Pistol A: Outbreak of West Nile virus infection in humans, Romania, July to October 2010. Euro Surveill 2011;16.
16. Lanciotti RS, Ebel GD, Deubel V, Kerst AJ, Murri S, Meyer R, Bowen M, McKinney N, Morrill WE, et al: Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 2002;298:96-105. (Pubitemid 34734883)
17. Vazquez A, Sanchez-Seco MP, Ruiz S, Molero F, Hernandez L, Moreno J, Magallanes A, Tejedor CG, Tenorio A: Putative new lineage of West Nile virus, Spain. Emerg Infect Dis 2010;16:549-552.
18. Guirakhoo F, Bolin RA, Roehrig JT: The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 1992;191:921-931. (Pubitemid 23022496)
19. Yamshchikov VF, Compans RW: Processing of the intracellular form of the West Nile virus capsid protein by the viral NS2B-NS3 protease: an in vitro study. J Virol 1994;68:5765-5771. (Pubitemid 24258592)
20. Roosendaal J, Westaway EG, Khromykh A, Mackenzie JM: Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein. J Virol 2006;80:4623-4632.
21. Macdonald J, Tonry J, Hall RA, Williams B, Palacios G, Ashok MS, Jabado O, Clark D, Tesh RB, Briese T, Lipkin W: NS1 protein secretion during the acute phase of West Nile virus infection. J Virol 2005;79:13924-13933. (Pubitemid 41552691)
22. Melian EB, Hinzman E, Nagasaki T, Firth AE, Wills NM, Nouwens AS, Blitvich BJ, Leung J, Funk A, et al: NS1′ of flaviviruses in the Japanese encephalitis virus serogroup is a product of ribosomal frameshifting and plays a role in viral neuroinvasiveness. J Virol 2010;84:1641-1647.
23. Diamond MS, Mehlhop E, Oliphant T, Samuel MA: The host immunologic response to West Nile encephalitis virus. Front Biosci 2009;14:3024-3034.
24. Davis CW, Nguyen HY, Hanna SL, Sánchez MD, Doms RW, Pierson TC: West Nile virus discriminates between DC-SIGN and DCSIGNR for cellular attachment and infection. J Virol 2006;80:1290-1301. (Pubitemid 43134086)
25. Mukhtar M, Harley S, Chen P, BouHamdan M, Patel C, Acheampong E, Pomerantz RJ: Primary isolated human brain microvascular endothelial cells express diverse HIV/SIV-associated chemokine coreceptors and DC-SIGN and L-SIGN. Virology 2002;297:78-88. (Pubitemid 34734912)
26. 3 integrin mediates virus entry into cells. J Biol Chem 2004;279:54533-54541.
27. Gillespie LK, Hoenen A, Morgan G, Mackenzie JM: The endoplasmic reticulum provides the membrane platform for biogenesis of the flavivirus replication complex. J Virol 2010;84:10438-10447.
28. Hoenen A, Liu W, Kochs G, Khromykh AA, Mackenzie JM: West Nile virus-induced cytoplasmic membrane structures provide partial protection against the interferon-induced antiviral MxA protein. J Gen Virol 2007;88:3013-3017. (Pubitemid 350131239)
29. Stadler K, Allison SL, Schalich J, Heinz FX: Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 1997;71: 8475-8481. (Pubitemid 27446428)
30. Krishnan MN, Ng A, Sukumaran B, Gilfoy FD, Uchil PD, Sultana H, Brass AL, Adametz R, Tsui M, Qian F, Montgomery RR, Lev S, Mason PW, Koski RA, Elledge SJ, Xavier RJ, Agaisse H, Fikrig E: RNA interference screen for human genes associated with West Nile virus infection. Nature 2008;455:242-245.
31. Davis CT, Ebel GD, Lanciotti RS, Brault AC, Guzman H, Siirin M, Lambert A, Parsons RE, Beasley DW, et al: Phylogenetic analysis of North American West Nile virus isolates, 2001-2004: evidence for the emergence of a dominant genotype. Virology 2005;342:252-265.
32. Brault AC, Huang CY, Langevin SA, Kinney RM, Bowen RA, Ramey WN, Panella NA, Holmes EC, Powers AM, Miller BR: A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet 2007;39:1162-1166. (Pubitemid 47340649)
33. Botha EM, Markotter W, Wolfaardt M, Paweska JT, Swanepoel R, Palacios G, Nel LH, Venter M: Genetic determinants of virulence in pathogenic lineage 2 West Nile virus strains. Emerg Infect Dis 2008;14:222-230. (Pubitemid 351213671)
34. Beasley DW, Whiteman MC, Zhang S, Huang CY, Schneider BS, Smith DR, Gromowski GD, Higgs S, Kinney RM, Barrett AD: Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J Virol 2005;79:8339-8347. (Pubitemid 40853537)
35. Murata R, Eshita Y, Maeda A, Maeda J, Akita S, Tanaka T, Yoshii K, Kariwa H, Umemura T, Takashima I: Glycosylation of the West Nile virus envelope protein increases in vivo and in vitro viral multiplication in birds. Am J Trop Med Hyg 2010;82:696-704.
36. Kilpatrick AM, Meola MA, Moudy RM, Kramer LD: Temperature, viral genetics, and the transmission of West Nile virus by Culex pipiens mosquitoes. PLoS Pathog 2008;4:e1000092.
37. Samuel MA, Diamond MS: Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 2005;79:13350-13361. (Pubitemid 41508149)
38. Keller BC, Fredericksen BL, Samuel MA, Mock RE, Mason PW, Diamond MS, Gale M Jr: Resistance to α/β interferon is a determinant of West Nile virus replication fitness and virulence. J Virol 2006;80:9424-9434. (Pubitemid 44435621)
39. Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M Jr: Establishment and maintenance of the innate antiviral response to West Nile virus involves both RIG-I and MDA5 signaling through IPS-1. J Virol 2008;82:609-616.
40. Daffis S, Suthar MS, Szretter KJ, Gale M Jr, Diamond MS: Induction of IFN-β and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog 2009;5:e1000607.
41. Suthar MS, Ma DY, Thomas S, Lund JM, Zhang N, Daffis S, Rudensky AY, Bevan MJ, Clark EA, Kaja MK, et al: IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog 2010;6:e1000757.
42. Wang P, Arjona A, Zhang Y, Sultana H, Dai J, Yang L, LeBlanc PM, Doiron K, Saleh M, Fikrig E: Caspase-12 controls West Nile virus infection via the viral RNA receptor RIG-I. Nat Immunol 2010;11:912-919.
43. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA: Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004;10:1366-1373. (Pubitemid 40022719)
44. Daffis S, Samuel MA, Suthar MS, Gale M Jr, Diamond MS: Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol 2008;82:10349-10358. (Pubitemid 352691152)
45. Town T, Bai F, Wang T, Kaplan AT, Qian F, Montgomery RR, Anderson JF, Flavell RA, Fikrig E: Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 2009;30:242-253.
46. Samuel MA, Whitby K, Keller BC, Marri A, Barchet W, Williams BR, Silverman RH, Gale M Jr, Diamond MS: PKR and RNase L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol 2006;80:7009-7019. (Pubitemid 44025199)
47. Rios JJ, Fleming JG, Bryant UK, Carter CN, Huber JC, Long MT, Spencer TE, Adelson DL: OAS1 polymorphisms are associated with susceptibility to West Nile encephalitis in horses. PLoS One 2010;5:e10537.
48. Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A, Gershoni-Yahalom O, Brient-Litzler E, et al: NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J Immunol 2009;183:2610-2621.
49. King NJ, Kesson AM: Interferon-independent increases in class I major histocompatibility complex antigen expression follow flavivirus infection. J Gen Virol 1988;69:2535-2543.
50. Mehlhop E, Diamond MS: Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 2006;203:1371-1381. (Pubitemid 43736604)
51. Fuchs A, Lin TY, Beasley DW, Stover CM, Schwaeble WJ, Pierson TC, Diamond MS: Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe 2010;8: 186-195.
52. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E: Modulation of dengue virus infection in human cells by α-, β-, and γ-interferons. J Virol 2000;74:4957-4966. (Pubitemid 30313834)
53. Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, Errett J, Lin TY, Schneller S, Zust R, Dong H, et al: 2′-O-methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 2010;468:452-456.
54. Fredericksen BL, Smith M, Katze MG, Shi PY, Gale M Jr: The host response to West Nile virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J Virol 2004;78: 7737-7747. (Pubitemid 38915920)
55. Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA: A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit α/β interferon induction and attenuates virus virulence in mice. J Virol 2006;80:2396-2404. (Pubitemid 43271545)
56. Laurent-Rolle M, Boer EF, Lubick KJ, Wolfinbarger JB, Carmody AB, Rockx B, Liu W, Ashour J, Shupert WL, Holbrook MR, et al: The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol 2010;84:3503-3515.
57. Evans JD, Seeger C: Differential effects of mutations in NS4B on West Nile virus replication and inhibition of interferon signaling. J Virol 2007;81:11809-11816. (Pubitemid 47623813)
58. Arjona A, Ledizet M, Anthony K, Bonafé N, Modis Y, Town T, Fikrig E: West Nile virus envelope protein inhibits dsRNA-induced innate immune responses. J Immunol 2007;179:8403-8409.
59. Wilson JR, de Sessions PF, Leon MA, Scholle F: West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. J Virol 2008;82:8262-8271.
60. Baronti C, Sire J, de Lamballerie X, Quérat G: Nonstructural NS1 proteins of several mosquito-borne flavivirus do not inhibit TLR3 signaling. Virology 2010;404:319-330.
61. Chung KM, Liszewski MK, Nybakken G, Davis AE, Townsend RR, Fremont DH, Atkinson JP, Diamond MS: West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci USA 2006;103:19111-19116. (Pubitemid 350002836)
62. Avirutnan P, Fuchs A, Hauhart RE, Somnuke P, Youn S, Diamond MS, Atkinson JP: Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med 2010;207:793-806.
63. Juul-Madsen HR, Viertlboeck B, Smith AL, Göbel TWF: Avian innate immune responses; in Davidson F, Kaspers B, Schat KA (eds): Avian Immunology. London, Academic Press, 2008, pp 129-158.
64. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M: B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003;77:2578-2586. (Pubitemid 36222782)
65. Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M: A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 2003;198:1853-1862. (Pubitemid 38032118)
66. Shrestha B, Ng T, Chu HJ, Noll M, Diamond MS: The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 2008;26:2020-2033.
67. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS: Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 2007;81:11828-11839.
68. Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, Clijstersvan der Horst M, de Jong M, Jongeneelen M, et al: Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile virus. J Virol 2006;80:6982-6992. (Pubitemid 44025197)
69. Mehlhop E, Nelson S, Jost CA, Gorlatov S, Johnson S, Fremont DH, Diamond MS, Pierson TC: Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 2009;6:381-391.
70. Chung KM, Thompson BS, Fremont DH, Diamond MS: Antibody recognition of cell surface-associated NS1 triggers Fc-γ receptor-mediated phagocytosis and clearance of West Nile virus-infected cells. J Virol 2007;81:9551-9555. (Pubitemid 47311499)
71. Douglas MW, Kesson AM, King NJ: CTL recognition of west Nile virus-infected fibroblasts is cell cycle dependent and is associated with virus-induced increases in class I MHC antigen expression. Immunology 1994;82:561-570. (Pubitemid 24263382)
72. Shrestha B, Diamond MS: Role of CD8+ T cells in control of West Nile virus infection. J Virol 2004;78:8312-8321. (Pubitemid 38944315)
73. Sitati EM, Diamond MS: CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol 2006;80:12060-12069. (Pubitemid 44904356)
74. Wang Y, Lobigs M, Lee E, Müllbacher A: Exocytosis and Fas mediated cytolytic mechanisms exert protection from West Nile virus induced encephalitis in mice. Immunol Cell Biol 2004;82:170-173. (Pubitemid 38594648)
75. Pruitt AA: Central nervous system infections in cancer patients. Semin Neurol 2004;24:435-452.
76. Wang Y, Lobigs M, Lee E, Müllbacher A: CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 2003;77:13323-13334. (Pubitemid 37494327)
77. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM: Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005;202:1087-1098. (Pubitemid 41464502)
78. Klein RS, Lin E, Zhang B, Luster AD, Tollett J, Samuel MA, Engle M, Diamond MS: Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol 2005;79:11457-11466. (Pubitemid 41170686)
79. Sitati E, McCandless EE, Klein RS, Diamond MS: CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis. J Virol 2007;81:9801-9811. (Pubitemid 350067684)
80. Diamond MS: Virus and host determinants of West Nile virus pathogenesis. PLoS Pathog 2009;5:e1000452.
81. Lanteri MC, O'Brien KM, Purtha WE, Cameron MJ, Lund JM, Owen RE, Heitman JW, Custer B, Hirschkorn DF, Tobler LH, et al: Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest 2009;119:3266-3277.
82. Vaughan K, Greenbaum J, Blythe M, Peters B, Sette A: Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology. Viral Immunol 2010;23:259-284.
83. McMurtrey CP, Lelic A, Piazza P, Chakrabarti AK, Yablonsky EJ, Wahl A, Bardet W, Eckerd A, Cook RL, Hess R, et al: Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes. Proc Natl Acad Sci USA 2008;105:2981-2986. (Pubitemid 351723654)
84. Kim S, Li L, McMurtrey CP, Hildebrand WH, Weidanz JA, Gillanders WE, Diamond MS, Hansen TH: Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T-cell immunity against lethal West Nile virus infection. J Immunol 2010;184:4423-4430.
85. Brien JD, Uhrlaub JL, Hirsch A, Wiley CA, Nikolich-Zugich J: Key role of T-cell defects in age-related vulnerability to West Nile virus. J Exp Med 2009;206:2735-2745.
86. Gardner IA, Wong SJ, Ferraro GL, Balasuriya UB, Hullinger PJ, Wilson WD, Shi PY, MacLachlan NJ: Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California. Vet Res 2007;38:109-116.
87. Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ: Equine vaccine for West Nile virus. Dev Biol (Basel) 2003;114: 221-227.
88. Samina I, Khinich Y, Simanov M, Malkinson M: An inactivated West Nile virus vaccine for domestic geese - efficacy study and a summary of 4 years of field application. Vaccine 2005;23:4955-4958. (Pubitemid 41242873)
89. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J: Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010;28:632-649.
90. El Garch H, Minke JM, Rehder J, Richard S, Edlund Toulemonde C, Dinic S, Andreoni C, Audonnet JC, Nordgren R, Juillard V: A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet Immunol Immunopathol 2008;123:230-239.
91. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning ML: West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001;75:4040-4047. (Pubitemid 32410116)
92. Wang T, Anderson JF, Magnarelli LA, Wong SJ, Koski RA, Fikrig E: Immunization of mice against West Nile virus with recombinant envelope protein. J Immunol 2001;167:5273-5277. (Pubitemid 33009765)
93. Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, Osterhaus AD: Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine 2008;26:153-157. (Pubitemid 50008834)
94. Lieberman MM, Nerurkar VR, Luo H, Cropp B, Carrion R Jr, de la Garza M, Coller BA, Clements D, Ogata S, et al: Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol 2009;16:1332-1337.
95. Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF: A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J 2010;7:146.
96. Bellier B, Huret C, Miyalou M, Desjardins D, Frenkiel MP, Despres P, Tangy F, Dalba C, Klatzmann D: DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 2009;27:5772-5780.
97. Demento SL, Bonafé N, Cui W, Kaech SM, Caplan MJ, Fikrig E, Ledizet M, Fahmy TM: TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol 2010;185:2989-2997.
98. Widman DG, Ishikawa T, Giavedoni LD, Hodara VL, Garza Mde L, Montalbo JA, Travassos Da Rosa AP, Tesh RB, Patterson JL, Carrion R Jr, Bourne N, Mason PW: Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection. Am J Trop Med Hyg 2010;82:1160-1167.
99. Schlick P, Kofler RM, Schittl B, Taucher C, Nagy E, Meinke A, Mandl CW: Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations. Vaccine 2010;28:5903-5909.
100. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, et al: A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007;196:1732-1740. (Pubitemid 351411932)
101. Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, Ross TM: Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol J 2010;7:95.
102. Ramanathan MP, Kutzler MA, Kuo YC, Yan J, Liu H, Shah V, Bawa A, Selling B, Sardesai NY, Kim JJ, Weiner DB: Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine 2009;27:4370-4380.
103. Kutzler MA, Weiner DB:DNA vaccines: ready for prime time? Nat Rev Genet 2008;9:776-788.
104. Schneeweiss A, Chabierski S, Salomo M, Al-Robayi S, Delaroque N, Grunwald T, Bürki K, Liebert UG, Ulbert S: A DNA vaccine encoding the E protein of West Nile Virus is protective and can be boosted by recombinant domain DIII Vaccine. Vaccine, in press.